NEW YORK ─ Norwegian firm Pre Diagnostics is preparing to enter the market for Alzheimer's disease testing using a monocyte blood immunoassay that analyzes the inside of innate immune cells to detect disease before there are symptoms.
The assay, called PreADx, uses intracellular measurements to monitor the ongoing clearance from the brain of amyloid-beta (Aβ) plaque, a hallmark of Alzheimer's disease pathology.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.